Tanya B Dorff MD

Oncology•Duarte, CA

Genitourinary Oncology, Hematologic Oncology

Associate Professor of Medicine Section Chief, Division of Genitouronary Cancers City of Hope

Join to View Full Profile

1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-218-8233

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2005 - 2006
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2004 - 2005
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2003 - 2004
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2000 - 2003
David Geffen School of Medicine at UCLAClass of 2000

Certifications & Licensure

CA State Medical License 2003 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013

Clinical Trials

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
Short-Term Fasting: Impact on Toxicity Start of enrollment: 2009 Jul 09
ACTIVE_NOT_RECRUITING
NA
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2012 Sep 01
Unknown status
Phase 2
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer Start of enrollment: 2013 Jan 29
Active, not recruiting
Not Applicable
Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer Start of enrollment: 2009 Jan 01
Completed
Not Applicable
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer Start of enrollment: 2016 Aug 02
Terminated
Phase 1
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Start of enrollment: 2018 Nov 21
Active, not recruiting
Phase 2
A Study of Olaparib and Durvalumab in Prostate Cancer Start of enrollment: 2019 Mar 07
Terminated
Phase 2
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2019 Aug 20
Active, not recruiting
Phase 1
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Start of enrollment: 2021 May 04
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion.
Benjamin D Mercier, Ameish Govindarajan, Daniela V Castro, Xiaochen Li, Errol J Philip
Cancer Medicine. 2025-04-01
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.
Arun A Azad, Louise Kostos, Neeraj Agarwal, Gerhardt Attard, Ian D Davis
European Urology. 2025-04-01
IDO Believe in Immunotherapy.
Peter D Zang, Tanya B Dorff
Clinical Cancer Research. 2025-03-18

Lectures

Closing the Gap: Knowledge Gaps and Interpreting Current Data in the Era of Novel Imaging — Medical...
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
A randomized phase II clinical trial of a fasting-mimic diet prior to chemotherapy to evaluate the impact on toxicity and efficacy.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Radiographic PFS in Metastatic CRPC More Than Doubles with Novel CombinationFebruary 13th, 2025
CAR-T Immunotherapy for Prostate Cancer?September 16th, 2024
Overview of Efficacy and Safety Data of Combination Therapy with PARPi and NHAsMarch 27th, 2023
Join now to see all